Drugs / EVO301
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06723405 | Feb → Nov 2025 | atopic eczema | Evommune, Inc. | Completed | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-02-10 | Evommune, Inc. | Results Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis evommune.com ↗
Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced positive top-line results from its randomized, double-blind, placebo-controlled Phase 2a trial evaluating EVO301. |
All press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-10-01 | Evommune, Inc. | Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress evommune.com ↗ |
| 2026-09-23 | Evommune, Inc. | Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress evommune.com ↗ |
| 2026-05-08 | AprilBio Co., Ltd. | 에이프릴 美 파트너 에보뮨, ‘EVO301’ 적응증 확대 검토···UC·심혈관 정조준 aprilbio.com ↗ |
| 2026-02-10 | Evommune, Inc. | Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis evommune.com ↗ |
| 2025-12-10 | AprilBio Co., Ltd. | 에보뮨, 'EVO301' 아토피 2a상 완료… 에이프릴바이오 수혜 기대감 aprilbio.com ↗ |
| 2025-03-17 | Evommune, Inc. | Evommune Initiates Phase 2 Trial of IL-18 Targeted Fusion Protein, EVO301, in Adult Patients with Atopic Dermatitis evommune.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EVO301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06723405 ↗ |
| Route | Intravenous | “intravenous EVO301” NCT06723405 ↗ |